Carotuximab API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Carotuximab API 1268714-50-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Carotuximab. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Carotuximab
- Synonyms:
- Chimeric anti-CD105 antibody , GAMMA1 HEAVY CHAIN (1-448) (MUS MUSCULUS VH (IGHV6-6*01-(IGHD) -IGHJ2*01) (8.10.9) (1-118) -HOMO SAPIENSIGHG1*01, GM17,1 (CH1 (119-216), HINGE (217-231), CH2(232-341), CH3 (342-446), CHS (447-448)) (119-448)), (221-213')-DISULFIDE WITH KAPPA LIGHT CHAIN , IMMUNOGLOBULIN G1-KAPPA, ANTI-(HUMAN ENDOGLIN (CD105 ANTIGEN)) HUMAN MOUSE CHIMERIC MONOCLONAL ANTIBODY .GAMMA.1 HEAVY CHAIN (1-448) (MOUSE VH (MUS MUSCULUS IGHV6-6*01 (98%) (IGHD)-IGHJ2*01 (87%)) (8.10.9) (1-118) -HOMO SAPIENS IGHG1*01 (119-448)) (221-2 , IMMUNOGLOBULIN G1, ANTI-(HUMAN ENDOGLIN) (HUMAN-MUS MUSCULUS MONOCLONAL TRC105 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TRC105 .KAPPA.-CHAIN, DIMER
- Cas Number:
- 1268714-50-6
- DrugBank number:
- DB06322
- Unique Ingredient Identifier:
- YB2EWE6139
General Description:
Carotuximab is a chemical compound identified by the CAS number 1268714-50-6. It is known for its distinct pharmacological properties and applications.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in solid tumors. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Carotuximab functions by: TRC105 is a first-in-class human chimeric monoclonal antibody that inhibits tumor growth by binding to CD105 (endoglin), a receptor over-expressed on proliferating endothelium that is required for angiogenesis (growth of new blood vessels). TRC105 has shown activity, as monotherapy or when combined with chemotherapy, in pre-clinical studies of breast and colorectal cancer. Pre-clinical data also indicate CD105 expression is increased following treatment of human cancer with anti-VEGF therapy. The target of TRC105 shares many features with the VEGF receptor. Most importantly, both the VEGF and CD105 receptors are essential for angiogenesis, in that deletion of either receptor prevents blood vessel formation in utero. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Carotuximab belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.
Categories:
Carotuximab is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Antibodies, Blood Proteins, Globulins, Immunoglobulins, Immunoproteins, Proteins, Serum Globulins. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Carotuximab is a type of Other substances
The pharmaceutical industry encompasses a diverse range of active pharmaceutical ingredients (APIs) that are used in the production of various medications. One category of APIs is known as other substances. This category includes substances that do not fall under the conventional classifications such as antibiotics, analgesics, or antihypertensives.
Other substances in pharmaceutical APIs consist of a broad array of chemical compounds with unique properties and applications. These substances play a crucial role in the formulation and development of specialized medications, catering to specific therapeutic needs. The category encompasses various substances like excipients, solvents, stabilizers, and pH adjusters.
Excipients are inert substances that aid in the manufacturing process and enhance the stability, bioavailability, and patient acceptability of pharmaceutical formulations. Solvents are used to dissolve other ingredients and facilitate their incorporation into the final product. Stabilizers ensure the integrity and shelf life of medications by preventing degradation or chemical changes. pH adjusters help maintain the desired pH level of a formulation, which can influence the drug's efficacy and stability.
Pharmaceutical manufacturers carefully select and incorporate specific other substances into their formulations, adhering to regulatory guidelines and quality standards. These substances undergo rigorous testing and evaluation to ensure their safety, efficacy, and compatibility with the desired pharmaceutical product. By employing other substances in API formulations, pharmaceutical companies can optimize drug delivery, improve patient compliance, and enhance therapeutic outcomes.
In summary, the other substances category of pharmaceutical APIs comprises a diverse range of chemicals, including excipients, solvents, stabilizers, and pH adjusters. These substances contribute to the formulation, stability, and performance of medications, enabling pharmaceutical manufacturers to develop specialized products that meet specific therapeutic requirements.
